November 29, 2016 - By Richard Conner · 0 Comments
The stock of Clovis Oncology Incorporated (NASDAQ:CLVS) registered a decrease of 7.93% in short interest. CLVS’s total short interest was 11.21 million shares in November as published by FINRA. Its down 7.93% from 12.18M shares, reported previously. With 1.78M shares average volume, it will take short sellers 6 days to cover their CLVS’s short positions. The short interest to Clovis Oncology Incorporated’s float is 62.04%. About 1.50 million shares traded hands. Clovis Oncology Inc (NASDAQ:CLVS) has risen 138.99% since April 26, 2016 and is uptrending. It has outperformed by 133.73% the S&P500.
Clovis Oncology, Inc. is a biopharmaceutical firm focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The company has a market cap of $1.28 billion. The Firm is developing approximately three product candidates: Rociletinib, Rucaparib and Lucitanib. It currently has negative earnings. Rociletinib is an oral epidermal growth factor receptor , mutant-selective covalent inhibitor that is under review with the United States and European regulatory authorities for the treatment of non-small cell lung cancer (NSCLC) in patients with activating EGFR mutations, as well as the resistance mutation, T790M.
Insitutional Activity: The institutional sentiment increased to 2 in Q2 2016. Its up 1.00, from 1 in 2016Q1. The ratio is positive, as 36 funds sold all Clovis Oncology Inc shares owned while 26 reduced positions. 18 funds bought stakes while 44 increased positions. They now own 36.50 million shares or 0.57% less from 36.71 million shares in 2016Q1.
Balyasny Asset Limited Liability Company reported 75,000 shares or 0.01% of all its holdings. Legal & General Group Public Limited Com, a United Kingdom-based fund reported 8,483 shares. Gemmer Asset Mngmt Limited has invested 0% of its portfolio in Clovis Oncology Inc (NASDAQ:CLVS). Swiss Natl Bank accumulated 0% or 55,050 shares. Atwood & Palmer Inc reported 100 shares or 0% of all its holdings. Quantitative Systematic Strategies Ltd Liability Company last reported 49,852 shares in the company. Two Sigma Securities Ltd Com reported 10,042 shares or 0.08% of all its holdings. Bourgeon Capital Lc last reported 0.12% of its portfolio in the stock. Wells Fargo Communication Mn holds 0% or 15,037 shares in its portfolio. Credit Suisse Ag accumulated 0% or 122,697 shares. Nationwide Fund Advisors has 0% invested in the company for 20,623 shares. State Street Corp holds 1.64 million shares or 0% of its portfolio. Tower Cap Limited Liability Corp (Trc) owns 7,105 shares or 0.01% of their US portfolio. Old Mutual Global Investors (Uk) Limited has 0.02% invested in the company for 89,959 shares. American Grp last reported 0% of its portfolio in the stock.
Out of 9 analysts covering Clovis Oncology (NASDAQ:CLVS), 4 rate it a “Buy”, 1 “Sell”, while 4 “Hold”. This means 44% are positive. Clovis Oncology has been the topic of 24 analyst reports since September 10, 2015 according to StockzIntelligence Inc. As per Wednesday, August 24, the company rating was maintained by SunTrust. Suntrust Robinson maintained the stock with “Buy” rating in Friday, September 23 report. The stock of Clovis Oncology Inc (NASDAQ:CLVS) earned “Hold” rating by WallachBeth Capital on Tuesday, November 17. The firm has “Neutral” rating given on Monday, November 16 by Piper Jaffray. The company was initiated on Friday, August 5 by Suntrust Robinson. WallachBeth Capital maintained it with “Hold” rating and $22 target price in Monday, May 9 report. Chardan Capital Markets initiated the stock with “Sell” rating in Tuesday, October 25 report. The firm has “Neutral” rating given on Monday, November 16 by Mizuho. Stifel Nicolaus maintained the stock with “Buy” rating in Wednesday, September 21 report. The rating was maintained by Suntrust Robinson with “Buy” on Wednesday, August 24.
Clovis Oncology, Inc., incorporated on April 20, 2009, is a biopharmaceutical firm focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Firm is developing approximately three product candidates: Rociletinib, Rucaparib and Lucitanib. Rociletinib is an oral epidermal growth factor receptor (EGFR), mutant-selective covalent inhibitor that is under review with the United States and European regulatory authorities for the treatment of non-small cell lung cancer (NSCLC) in patients with activating EGFR mutations, as well as the resistance mutation, T790M. Rucaparib is an oral inhibitor of poly (ADP-ribose) polymerase (PARP) that is in advanced clinical development for the treatment of ovarian cancer. Lucitanib is an oral inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors 1-3 (VEGFR1-3) and platelet-derived growth factor receptors alpha and beta (PDGFR a/b).
Another recent and important Clovis Oncology Inc (NASDAQ:CLVS) news was published by Businesswire.com which published an article titled: “Robbins Arroyo LLP: Clovis Oncology, Inc. (CLVS) Misled Shareholders According …” on November 18, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Richard Conner